TY  - GEN
AU  - Braso-Maristany, Fara
AU  - Sansó, Miriam
AU  - Chic, Nuria
AU  - Martinez, Debora
AU  - Gonzalez-Farre, Blanca
AU  - Sanfeliu, Esthe
AU  - Ghiglione, Lucio
AU  - Carcelero, Esther
AU  - Garcia-Corbacho, Javier
AU  - Sanchez, Marcelo
AU  - Soy, Dolors
AU  - Jares, Pedro
AU  - Peg, Vicente
AU  - Saura, Cristina
AU  - Muñoz, Montserrat
AU  - Prat, Aleix
AU  - Vivancos, Ana
PY  - 2021
DO  - 10.3389/fonc.2021.710596
SN  - 2234-943X
UR  - https://hdl.handle.net/20.500.12105/23198
AB  - The immune checkpoint inhibitor atezolizumab is approved for PD-L1-positive triple-negative breast cancer (TNBC). However, no activity of atezolizumab in PD-L1-negative TNBC has been reported to date. Here, we present the case study of a woman with...
LA  - eng
PB  - Frontiers Media
KW  - Immunotherapy
KW  - Breast cancer
KW  - Biomarkers
KW  - ctDNA
KW  - Case report
TI  - Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer
TY  - research article
ER  -